AVANÇOS NO TRATAMENTO DA ANEMIA FALCIFORME

• DOI: https://doi.org/10.22533/at.ed.93719124021210

• Palavras-chave: Anemia falciforme; doença; hereditária; medicamentos, genéticas

• Keywords: Sickle cell anemia; illness; hereditary; medicines; genetics.

• Abstract: Sickle cell anemia (SCA) is a chronic disease involving certain clinical conditions resulting from hereditary, genetic and recessive changes. The hypothesis is that the therapeutic approach with the combination of treatments can improve the quality of life and prolong survival, causing a reduction in the patient's pain attacks and vascular complications. The general objective is to present possible advances in the treatment of sickle cell anemia, explore new medications and therapies that can prevent the progression of the disease, and reduce complications. We can conclude that treating sickle cell anemia is currently one of the biggest challenges in medicine, requiring a A multidisciplinary approach that ranges from preventative measures to advanced therapies such as herbal compounds, the development of new specific drugs and the exploration of gene therapies, offers expectations for patients and professionals, where consequently over a period of time the impact of anemia sickle cell disease can be significantly minimized. However, unequal access to these treatments remains an obstacle, especially in low- and middle-income countries, where the prevalence of the disease is higher.